Tiger Brokers

Samsung Epis Unit Signs $420 Million US Biosimilar Deal with Teva Pharmaceuticals

MT Newswires Live
Yesterday

Samsung Epis (KRX:0126Z0) said its unit Samsung Bioepis signed a $420 million partnership deal with Switzerland-based Teva Pharmaceuticals International to commercialize two biosimilar drugs in the US, according to a Friday filing with the Korea Exchange.

Under the deal, Samsung Bioepis will develop, manufacture, and supply SB2, a biosimilar to Remicade used in the treatment of Crohn's disease, ulcerative colitis, and rheumatoid arthritis, and SB4, a biosimilar to Enbrel used in the treatment of rheumatoid arthritis, psoriatic arthritis, and psoriasis.

Teva will handle US commercialization while sharing sales profits with Samsung Bioepis under a deal structure that includes up to $75 million in upfront payments, $75 million in launch milestones, and $270 million in sales milestones.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10